

Reference:	FOI.3750.20
Subject:	Biosimilar Adalimumab
Date of Request:	4 August 2020

Requested and response:

Please can you send me the following information?

Hywel Dda University Health Board (UHB) provides the number of patients and initiating departments for the information requested below, for the last twelve (12) months.

	FOI Question	Number of Patients	Initiating departments <i>e.g. rheumatology, dermatology, etc.</i>
1	How many patients (in the Trust) were initiated on ANTI TNF (originator and biosimilar) over the last 12 months?	197	Dermatology, Rheumatology & Gastroenterology
2a	How many patients (in the Trust) have been initiated on biosimilar adalimumab?	133	Dermatology, Rheumatology & Gastroenterology
2b	and what is the split by brand in the last 12 months for the following products?		
	• Amgevita	89	Dermatology, Rheumatology & Gastroenterology
	• Imraldi	57	Dermatology & Rheumatology
	• Hulio	0	
	• Hyrmioz	0	
	• Idacio	0	
3	How many patients have been initiated on these products?		
	• Guselkumab (Tremfya)	0	
	• Risankizumab (Skyrizi)	0	
	• Brodalumab (Kyntheum)	0	
	• Ixekizumab (Taltz)	0	